BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) has been identified as a high-growth momentum stock that aligns with Mark Minervini’s Trend Template. The company’s technical strength, combined with accelerating fundamentals, makes it a compelling candidate for growth-focused investors. Below, we examine why BCRX fits both the Minervini strategy and high-growth investing criteria.

Why BCRX Meets Minervini’s Trend Template

The Trend Template focuses on stocks exhibiting strong upward momentum, confirmed by moving averages and relative strength. BCRX checks all key criteria:

• Price Above Key Moving Averages:

  • Current price ($10.34) is above the 50-day ($8.00), 150-day ($7.89), and 200-day ($7.87) moving averages.
  • The 50-day MA is above both the 150-day and 200-day MAs, confirming bullish alignment.

• Upward-Trending Averages:

  • The 150-day and 200-day MAs are rising, reinforcing long-term strength.

• Strong Relative Strength:

  • BCRX has a ChartMill Relative Strength (CRS) score of 95.62, meaning it outperforms nearly 96% of all stocks.

• Price Near 52-Week High:

  • The stock is trading within 7% of its 52-week high ($11.11) and 75% above its 52-week low ($5.92).

These factors indicate a stock in a sustained uptrend, a key requirement for Minervini’s strategy.

High Growth Momentum Fundamentals

Beyond technicals, BCRX shows strong growth metrics:

• Earnings & Revenue Growth:

  • EPS growth (TTM): +70.5%
  • Quarterly EPS growth (Q2Q): +100% (latest quarter)
  • Revenue growth (TTM): +41.7%
  • Quarterly revenue growth (Q2Q): +56.9%

• Positive Revisions & Estimate Beats:

  • EPS next-year revisions (3-month): +11.3%
  • Revenue next-year revisions (3-month): +11.3%
  • Beat EPS estimates in 2 of the last 4 quarters, with an average beat of 9.03%.

• Improving Profitability:

  • Recent quarterly profit margin turned positive (2.2%), signaling improving earnings potential.

These fundamentals suggest accelerating business performance, a hallmark of high-growth stocks.

Technical Summary

According to ChartMill’s technical report, BCRX scores a perfect 10/10 on technical health, with both short and long-term trends positive. However, the setup rating is 3/10, indicating that while the stock is strong, it may need consolidation before an optimal entry point.

Key takeaways:

• Strong uptrend with outperformance vs. the broader market.
• High relative strength within the biotechnology sector (top 6%).
• Support levels at $9.91 (daily) and $7.09 (weekly).

Our High Growth Momentum + Trend Template screener lists more high-growth stocks meeting these criteria.

Disclaimer

This is not investment advice. The analysis highlights observations at the time of writing, but investors should conduct their own research before making decisions.